IPO registrations (S-1, F-1) · Registrants
ALDER BIOPHARMACEUTICALS INC
- SEC CIK
- 1423824 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2014-03-19, last 2015-01-08; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2014-05-08; declared effective 2014-05-07
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Business address
- 11804 NORTH CREEK PARKWAY SOUTH, Bothell, WA 98011
- EIN
- 90-0134860
- EDGAR entity type
- operating
- Insiders and CEO pay
- ALDER BIOPHARMACEUTICALS INC on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2014-05-01)
- Final price
- $10.00 per share, below the range (424B4 filed 2014-05-08, an initial public offering)
- Shares sold
- 8,000,000
- Gross proceeds
- $80,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ALDR
- Lead underwriters
- Credit Suisse; Leerink Partners
- Syndicate
- Wells Fargo; Sanford C. Bernstein
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: LUNDBECK SEATTLE BIOPHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- Form D issuer: ALDER BIOPHARMACEUTICALS INC EXACT (CIK (EXACT))
- SEC filer: ALDER BIOPHARMACEUTICALS INC EXACT (CIK (EXACT))
- Person page: John V Jaggers Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Other))
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-03-19 | S-1 | S-1 (registration) | ALDER BIOPHARMACEUTICALS INC | 0001193125-14-104868 ↗ |
| 2014-04-25 | S-1/A | S-1/A (amendment) | ALDER BIOPHARMACEUTICALS INC | 0001193125-14-158365 ↗ |
| 2014-05-01 | S-1/A | S-1/A (amendment) | ALDER BIOPHARMACEUTICALS INC | 0001193125-14-177343 ↗ |
| 2014-05-07 | S-1MEF | S-1MEF (added securities) | ALDER BIOPHARMACEUTICALS INC | 0001193125-14-188165 ↗ |
| 2014-05-07 | EFFECT | EFFECT (declared effective) | ALDER BIOPHARMACEUTICALS INC | 9999999995-14-001359 ↗ |
| 2014-05-08 | 424B4 | 424B4 (final prospectus) | ALDER BIOPHARMACEUTICALS INC | 0001193125-14-190254 ↗ |
| 2014-12-22 | S-1 | S-1 (registration) | ALDER BIOPHARMACEUTICALS INC | 0001193125-14-450716 ↗ |
| 2015-01-05 | S-1/A | S-1/A (amendment) | ALDER BIOPHARMACEUTICALS INC | 0001193125-15-001743 ↗ |
| 2015-01-08 | S-1/A | S-1/A (amendment) | ALDER BIOPHARMACEUTICALS INC | 0001193125-15-004290 ↗ |
| 2015-01-08 | 424B4 | 424B4 (final prospectus) | ALDER BIOPHARMACEUTICALS INC | 0001193125-15-005060 ↗ |
| 2015-01-08 | EFFECT | EFFECT (declared effective) | ALDER BIOPHARMACEUTICALS INC | 9999999995-15-000063 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-05-01 | S-1/A | registration statement | $13.00–$15.00 | 7,150,000 | - | Nasdaq ALDR | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2014-05-08 | 424B4 | final prospectus | $10.00 | 8,000,000 | $80,000,000 | Nasdaq ALDR | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BAYLESS JON W | Other; TenPercentOwner | 4 | 2014–2015 | ||
| Benedict Larry | Officer | EVP and PAO; Sr. VP Finance | 14 | 2014–2019 | |
| Bisgaard Peter | Director | 1 | 2014 | ||
| BOCHNOWSKI JAMES J | TenPercentOwner | 2 | 2014 | ||
| BONDERMAN DAVID | TenPercentOwner | 2 | 2014 | ||
| Bridger Gary | Director; TenPercentOwner | 6 | 2014–2015 | ||
| COULTER JAMES G | TenPercentOwner | 2 | 2014 | ||
| Davidson Aaron | Director | 2 | 2014 | ||
| DELPHI BIOINVESTMENTS VII LP | TenPercentOwner | 2 | 2014 | ||
| Delphi Management Partners VII, L.L.C. | TenPercentOwner | 2 | 2014 | ||
| DELPHI VENTURES VII L P | TenPercentOwner | 2 | 2014 | ||
| DOMENIK STEPHEN L | Other; TenPercentOwner | 4 | 2014–2015 | ||
| DOUGLASS DAVID L | TenPercentOwner | 2 | 2014 | ||
| DOW STEPHEN M | Director; Director,TenPercentOwner | 11 | 2014–2017 | ||
| H.I.G. Venture Partners II, L.P. | TenPercentOwner | 2 | 2014 | ||
| H.I.G. Ventures - Alder, LLC | TenPercentOwner | 2 | 2014 | ||
| JAGGERS JOHN V | Other; TenPercentOwner | 4 | 2014–2015 | person page Fuzzy | |
| KIMZEY JACKIE R | Other; TenPercentOwner | 4 | 2014–2015 | ||
| Latham John A | Officer | Chief Scientific Officer | 36 | 2014–2019 | |
| Litton Mark James | Officer | Chief Business Officer | 25 | 2014–2018 | |
| McLean David J. | Other; TenPercentOwner | 4 | 2014–2015 | ||
| Montgomery Alan Bruce | Director | 8 | 2014–2019 | ||
| Novo A/S | TenPercentOwnerOther | 2 | 2014 | ||
| OXAAL JOHN T | Other; TenPercentOwner | 4 | 2014–2015 | ||
| PAKIANATHAN DEEPIKA | Director; Director,TenPercentOwner | 8 | 2014–2018 | ||
| Preston Heather | Director | 5 | 2014–2019 | ||
| ROEDER DOUGLAS A | TenPercentOwner | 2 | 2014 | ||
| Schatzman Randall C | Director,Officer | President and CEO | 21 | 2014–2018 | |
| SCHUELE ALAN R | Other; TenPercentOwner | 4 | 2014–2015 | ||
| Sevin Rosen Fund IX L.P. | Other; TenPercentOwner | 6 | 2014–2015 | ||
| Sevin Rosen IX Affiliates Fund L.P. | Other; TenPercentOwner | 6 | 2014–2015 | ||
| SIEGALL CLAY B | Director | 10 | 2014–2019 | ||
| Smith Jeffrey T L | Officer | Managing Director; Sr. VP Translational Medicine | 39 | 2014–2019 | |
| SRB Associates IX L.P. | Other; TenPercentOwner | 6 | 2014–2015 | ||
| STURIALE NICHOLAS G | Other; TenPercentOwner | 4 | 2014–2015 | ||
| TPG Group Holdings (SBS) Advisors, Inc. | TenPercentOwner | 2 | 2014 | ||
| Ventures West 8 Limited Partnership | TenPercentOwner | 2 | 2014 | ||
| Hassler Randal | Officer | EVP, Pharmaceutical Ops.; SVP, Manufacturing; SVP, Pharmaceutical Ops | 10 | 2014–2019 | |
| Cleveland Paul B | Director; Director,Officer | Interim President and CEO | 8 | 2015–2019 | |
| Carter Paul Rutherford | Director | 7 | 2015–2019 | ||
| Bucher James B | Officer | EVP & General Counsel; Sr. VP & General Counsel | 9 | 2016–2019 | |
| Whitaker Timothy M | Officer | Chief Medical Officer | 3 | 2016–2017 | |
| Sandoval Elisabeth | Officer | CCO & EVP, Corporate Strategy; Chief Commercial Officer | 5 | 2016–2018 | |
| YARNO WENDY L | Director | 7 | 2017–2019 | ||
| Lavelle Erin | Officer | Chief Commercial Officer; Chief Operating Officer | 5 | 2018–2019 | |
| Carter Eric G | Officer | Interim Chief Medical Officer | 2 | 2018 | |
| Green Jeremy | Director; TenPercentOwner | 9 | 2018–2019 | ||
| Redmile Group, LLC | Director | 9 | 2018–2019 | ||
| Azelby Robert | Director,Officer | President and CEO | 5 | 2018–2019 | |
| Campoy Carlos | Officer | Chief Financial Officer | 3 | 2018–2019 | |
| STRECK PAUL | Officer | Chief Medical Officer | 4 | 2019 | |
| Dac Nadia | Officer | Chief Commercial Officer | 3 | 2019 | |
| H LUNDBECK A S | TenPercentOwner | 2 | 2019 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2018-01-26 | ALDER BIOPHARMACEUTICALS INC | Biotechnology | $260,341,000 | $99,999,952 | 6 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | LUNDBECK SEATTLE BIOPHARMACEUTICALS, INC. | WA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | ALDER BIOPHARMACEUTICALS INC | WA | Form D private offerings | CIK (EXACT) |
| Patent assignee | ALDER BIOPHARMACEUTICALS, INC. | WA | Patents (USPTO) | name and state |
| SEC filer | ALDER BIOPHARMACEUTICALS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Alder BioPharmaceuticals, Inc. | WA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | LUNDBECK SEATTLE BIOPHARMACEUTICALS, INC. | EIN (EXACT) | ||
| Person page | John V Jaggers | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Other) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, WA first:
- PATHOGENESIS CORP WA
- DENDREON CORP WA
- CORUS PHARMA INC WA
- CytoDyn Inc. WA
- OMEROS CORP WA
- Trubion Pharmaceuticals, Inc WA
- Light Sciences Oncology Inc WA
- Cocrystal Pharma, Inc. WA
- PHASERX, INC. WA
- CHINOOK THERAPEUTICS, INC. WA
In other datasets, the same topic (Health) in WA:
- Nonprofit: ACUPUNCTURE RELIEF PROJECT (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health